Pharmacist in a marijuana plantation for medical use in João Pessoa, Paraíba – Cesar Mattos/ABRACE/Disclosure
The popular pressure was such that the Federal Council of Medicine decided revoke Resolution No. 2,324/2022, which drastically reduced the prescription of cannabis-based medicines. The decision will be published in the Official Gazette on Tuesday (25).
This Monday (24), CFM opened a public consultation About the subject. The form remains online.
A Resolution No. 2,324/2022, posted on October 14, stipulated that medical cannabis can only be used in the treatment of refractory epilepsy in children and adolescents with Dravet and Lennox-Gastaut Syndrome or Tuberous Sclerosis Complex. The rule also says that “the physician is prohibited from prescribing cannabidiol for a therapeutic indication other than that provided for in this Resolution, except in authorized clinical studies”. The professionals also could not “deliver lectures and courses on the use of cannabidiol and/or products derived from Cannabis outside the scientific environment, as well as make publicity”.
The measure, initially valid for three years, was a response by the institution to the increase in the import numbers of cannabis-based medicines, which had caused a “replacement of conventional and scientifically proven treatments”, according to the standard’s rapporteur, Rosylane Rocha.
No Twitterthe federal deputy Rafael Motta (PSB-RN) stated that the entity will open a new public consultation to discuss the application of cannabidiol to more than 20 different diseases.
Continues after advertising
Copyright © Abril Mídia S A. All rights reserved.
Quality and reliable information, just one click away. Subscribe SEE.